10 results about "Botulinum toxin a" patented technology

This invention provides a modified BoNT / A for treating facial wrinkles, wherein the modified BoNT / A is administered via intramuscular injection at multiple sites on an individual's face, wherein the modified BoNT / A is administered at a unit dose of greater than 1754 pg or greater than 8000 pg per site, wherein the multiple sites are selected from: up to two sites on the corrugator supercilii muscle and one site on the depressor supercilii muscle for treating glabellar lines; up to five sites on the frontalis muscle for treating forehead wrinkles; and up to three sites on the orbicularis oculi muscle for treating lateral canthal wrinkles, wherein the total dose of modified BoNT / A administered during treatment is up to 264,000 pg (and optionally greater than 88,000 pg), and wherein the modified BoNT / A comprises a BoNT / A light chain and a translocation domain (H N The structure domain), and the BoNT / B receptor binding domain (H C (structural domain).

The invention belongs to the field of biology, and particularly relates to a botulinum toxin A light chain mutant and application. The BoNT / A LC mutant is obtained by performing directed evolution optimization on the BoNT / A LC by adopting a phage-assisted evolution method, and compared with a wild type BoNT / A LC, the activity of the mutant is remarkably improved, the defects of an existing botulinum toxin product and the problems of drug resistance and the like can be overcome, and the BoNT / A LC mutant can be applied to the fields of medical beauty and medical treatment and has a wide application prospect.

The invention relates to the technical field of biology, and particularly discloses a preparation method and application of recombinant A-type botulinum toxin. According to the method disclosed by the invention, after the recombinantly expressed protoxin is combined with cation exchange filler, enzyme digestion and activation are realized by utilizing single protease, and then purification is carried out. The preparation method disclosed by the invention has the advantages of good convenience and small batch-to-batch difference, and the prepared recombinant A-type botulinum toxin also has obvious advantages in protein effectiveness and biological activity.

This invention relates to a botulinum toxin A1 precursor molecule, a nucleic acid molecule, an engineered bacterium, a method for preparing the same, and a method for preparing natural botulinum toxin A using the precursor molecule. The precursor molecule comprises a light chain and a heavy chain, and a linker region connecting the light and heavy chains. The amino acid sequence of the precursor molecule is shown in SEQ ID NO. 4. The light chain is the amino acid sequence from position 1 to position 444 of natural botulinum toxin A, as shown in SEQ ID NO. 5. The heavy chain sequence is the amino acid sequence from position 449 to position 1296 of natural botulinum toxin A, as shown in SEQ ID NO. 6. The amino acid sequence of the linker region is shown in SEQ ID NO. 11. This invention provides a safe process, and the resulting recombinant botulinum toxin not only has a sequence identical to the natural botulinum toxin active protein but also exhibits high activity, providing a low-cost, high-activity botulinum toxin product for clinical use.

A precise dose syringe for medical botulinum toxin is provided, which includes a syringe and a plunger handle. Multiple arc-shaped grooves are respectively provided on both sides of the plunger handle, and a scale line is processed on the front side of the plunger handle. A reminder mechanism and a quantitative mechanism are sleeved on the outer side of the plunger handle. The indicator arrow is located in front of the plunger handle, and the I-shaped block is connected to a thumb screw. The front side of the thumb screw is fixedly connected to a contact block, and the front side of the contact block is in contact with a back side of the plunger handle. The quantitative mechanism can make the injection dose of the syringe precise and controllable, while the reminder mechanism can remind doctors of the real-time injection amount during botulinum toxin injection.

A method of treating vertigo in a patient in need thereof comprises administering a botulinum toxin to the patient. The botulinum toxin may be administered by subcutaneous / intradermal injection. The subcutaneous / intradermal injection may be administered to and / or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, and a sacral nerve of the patient.

A precise dose syringe for medical botulinum toxin is provided, which includes a syringe and a plunger handle. Multiple arc-shaped grooves are respectively provided on both sides of the plunger handle, and a scale line is processed on the front side of the plunger handle. A reminder mechanism and a quantitative mechanism are sleeved on the outer side of the plunger handle. The indicator arrow is located in front of the plunger handle, and the I-shaped block is connected to a thumb screw. The front side of the thumb screw is fixedly connected to a contact block, and the front side of the contact block is in contact with a back side of the plunger handle. The quantitative mechanism can make the injection dose of the syringe precise and controllable, while the reminder mechanism can remind doctors of the real-time injection amount during botulinum toxin injection.

This invention relates to a botulinum toxin A1 precursor molecule, a nucleic acid molecule, an engineered recombinant baculovirus, a method for preparing the same, and a method for preparing natural botulinum toxin A using the precursor molecule. The precursor molecule comprises a light chain and a heavy chain, and a linker region connecting the light and heavy chains. The amino acid sequence of the precursor molecule is shown in SEQ ID NO. 2. The light chain is the amino acid sequence from position 1 to position 444 of natural botulinum toxin A, as shown in SEQ ID NO. 5. The heavy chain sequence is the amino acid sequence from position 449 to position 1296 of natural botulinum toxin A, as shown in SEQ ID NO. 6. The amino acid sequence of the linker region is shown in SEQ ID NO. 11. This invention provides a safe process, and the resulting recombinant botulinum toxin not only has a sequence identical to the active protein of natural botulinum toxin but also exhibits high activity, providing a low-cost, high-activity botulinum toxin product for clinical use.

The present invention provides a modified BoNT / A for use in treating facial lines, wherein the modified BoNT / A is administered by intramuscular injection at a plurality of sites of the face of the subject, wherein the modified BoNT / A is administered by way of a unit dose of greater than 1754 pg or greater than 8000 pg) of modified BoNT / A per site, wherein the plurality of sites are selected from: up to two sites of a corrugator muscle and one site of a procerus muscle for treating glabellar lines, up to five sites of a frontalis muscle for treating forehead lines, and up to three sites of an orbicularis oculi muscle for treating lateral canthal lines, wherein the total dose of modified BoNT / A administered during the treatment is up to 264,000 pg (and optionally greater than 88,000 pg), and wherein the modified BoNT / A comprises a BoNT / A light-chain and translocation domain (HN domain), and a BoNT / B receptor binding domain (HC domain).

A non-invasive technique for enhancing the delivery of botulinum toxins through the skin, utilizing low-frequency ultrasound as a pretreatment, is provided. The ultrasound- facilitated transdermal delivery approach provides an efficient, comfortable and needle-free alternative to conventional injection-based administration of botulinum toxins, and is applicable to a wide range of therapeutic and cosmetic uses, including, reducing or modulating sweat gland activity, relaxing or inhibiting muscle activity, alleviating pain, minimizing wrinkles or fine lines, and treating or preventing pathologies such as neuromuscular and neurological disorders, glandular dysfunction, urological conditions, ophthalmological disorders, gastrointestinal conditions and / or respiratory disorders